Phaseline

Companies › Turning Point Therapeutics

Turning Point Therapeutics: clinical trials, targets and expected readouts

2 active drug programs in 6 registered trials: 4 Phase 1, 2 Phase 2; Oncology; next expected readout Mar 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
elzovantinib (TPX-0022)
MET/CSF1R/SRC inhibitor
MET, CSF1R, SRCPhase 1Advanced Solid TumorMar 2027
Repotrectinib (TPX-0005)
Nerve growth factor receptor Trk-A inhibitor; Neurotrophic tyrosine kinase receptor type 2 inhibitor; Proto-oncogene tyrosine-protein kinase ROS inhibitor
NTRK1, NTRK2, ROS1, NTRK3, CD74Phase 1Locally Advanced Solid Tumors; NSCLC; NSCLC Stage IV; Advanced CancerSep 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT03993873elzovantinib (TPX-0022)Phase 1Advanced Solid TumorOncologyMar 2027
NCT06315010Repotrectinib (TPX-0005)Phase 2NSCLCOncologyMar 2027
NCT04094610Repotrectinib (TPX-0005)Phase 1Locally Advanced Solid TumorsOncologySep 2027
NCT03093116Repotrectinib (TPX-0005)Phase 1Locally Advanced Solid TumorsOncologyFeb 2028
NCT05004116Repotrectinib (TPX-0005)Phase 1Advanced CancerOncologyAug 2028
NCT06552234Repotrectinib (TPX-0005)Phase 2NSCLC Stage IVOncologySep 2031

Targets

MET (1) CSF1R (1) SRC (1) NTRK1 (1) NTRK2 (1) ROS1 (1) NTRK3 (1) CD74 (1)

Companies with the same targets

AstraZeneca Xuanzhu Biopharmaceutical Nuvation Bio Roche Bristol-Myers Squibb IDEAYA Biosciences Johnson & Johnson (Janssen) Exelixis AbbVie Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.